Enveda pricing
Enveda funds its own therapeutics pipeline through equity rather than product sales. Named investors across its rounds include Catalio Capital Management, Kinnevik, FPV, Premji Invest, Baillie Gifford, Lux Capital, Dimension, True Ventures, Durable Capital Partners, ICONIQ, Lightspeed, Cresset Partners, Sanofi, The Nature Conservancy and Henry R. Kravis, and the September 2026 Series E brought total capital raised past $845 million.
How Enveda pricing works
- Pricing model
- Not applicable. Therapeutics developer with no commercial product; funded by venture capital, with future revenue dependent on its own pipeline or on partnering and licensing rather than on sales.
- Implementation
- Not applicable. No customer deployment exists.
- Business associate agreement
- Not applicable. No covered entity customers and no business associate relationship, as the company develops its own therapeutics rather than supplying software or services to providers.
Terms of the Microsoft collaboration and the Gates Foundation partnership are not public.
Enveda pricing against its alternatives
Published prices for Enveda and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- EEnvedaNot applicable
- VValo HealthNo published price
- BBiolojic DesignNo published price
- SSuperluminal MedicinesNo published price
- NNumerion LabsNo published price
- PPostEraNo published price
- CCellarityNot applicable
- CChemifyNo published price
- EEarendil LabsNo published price
Enveda pricing, answered
How much does Enveda cost?
Enveda does not publish a price. Enveda funds its own therapeutics pipeline through equity rather than product sales. Named investors across its rounds include Catalio Capital Management, Kinnevik, FPV, Premji Invest, Baillie Gifford, Lux Capital, Dimension, True Ventures, Durable Capital Partners, ICONIQ, Lightspeed, Cresset Partners, Sanofi, The Nature Conservancy and Henry R.
Does Enveda offer a business associate agreement?
Not applicable. No covered entity customers and no business associate relationship, as the company develops its own therapeutics rather than supplying software or services to providers.